19Sep
19Sep
DetraPel: Advanced Materials Company Secures $7.6 Million
DetraPel – the advanced materials company that manufactures sustainable coatings – recently announced the completion of its $7.6 million Series A funding led by Material Impact. And additional investors in this round include multi-billion dollar packaging ink manufacturer INX International, Touchdown Ventures, FitzGate Ventures, Boro Capital, Icebook Investments, and others. The new funding round will enable DetraPel to build on the market traction of the company’s recently rebranded industrial arm, Impermea Materials. And DetraPel has also rebranded its consumer operations...
12Sep
DetraPel Closes $7.6M Series A Funding
DetraPel, the advanced materials company that manufactures sustainable coatings announced the completion of its $7.6M Series A funding led by Material Impact. Additional investors in this round include multi-billion dollar packaging ink manufacturer, INX International, along with Touchdown Ventures, FitzGate Ventures, Boro Capital, Icebook Investments, and others. The newly raised funds will allow DetraPel to build on the market traction of the company’s recently rebranded industrial arm, Impermea Materials. DetraPel has also rebranded its consumer operations to ProofPlus. The capital...
02Sep
Q&A: What you need to know about assistive eye wear for blind, visually impaired patients
According to the Optometrists Network, one in six adults older than 45 years and one in four older than 75 has low vision, which can affect one’s ability to perform multiple tasks such as reading, driving and viewing TV or computer screens. Some wearable visual aid devices, including the OrCam MyEye Pro and eSight, Envision and IrisVision glasses, use small cameras and enhanced footage on small screens to help improve residual vision in those with low vision. "Electronic assistive glasses...
01Sep
Akston Biosciences wins Innovation Award at Animal Health Summit
Akston Biosciences Corp, a Massachusetts-based startup focused on developing long-acting protein therapeutics for pets, has received the Innovation Award at the the 2023 Animal Health Summit hosted by KC Animal Health Corridor at the Midland Theatre in Kansas City, Missouri. This is the highest distinction a company can achieve at the event. During the Emerging Companies part of the summit which consisted of a “Shark Tank-style” presentation, Akston Biosciences was among 13 animal health startups to describe their visions for...
30Aug
Myomo Announces Closing of $4.4 Million Public Offering
Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "reasonable best efforts" public offering of 7,333,334 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.60 per share for aggregate gross proceeds of approximately $4.4 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds...
23Aug
From the US to EU, how EcoSoul Home clocked over Rs 100 cr in GMV by exporting sustainable products
Launched in August 2020, eco-friendly home essentials brand EcoSoul Home aims to accelerate the movement towards a sustainable lifestyle by tapping Earth’s most renewable sources. With a diverse range of products in kitchen ware, dinnerware and cutlery, the brand claims to drive the 3As of sustainability — awareness, availability and affordability. It also seeks to support the SME sector by giving them access and exposure to global markets. Rahul Singh, Co-founder, EcoSoul Home, tells ET Online about their focused goals...
19Aug
Alzheimer’s Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004
Astrocyte Pharmaceuticals Inc., a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer's Drug Discovery Foundation, and other investors. The funding will accelerate the clinical development of AST-004, a highly promising therapeutic candidate aimed at treating a broad array of acute brain injuries including stroke and traumatic brain injury (TBI), and further...
18Aug
Akston Biosciences to Focus on Strong Animal Health Pipeline
Akston Biosciences Corporation announced today that it will focus on inventing, developing, and manufacturing breakthrough protein therapeutics for Companion Animal Health, utilizing its versatile Ambifect™ Fc-fusion platform and its Beverly, Massachusetts cGMP biologics manufacturing facility. Akston is spinning off its infectious disease vaccine and human Type 1 Diabetes prevention lines of business into two wholly-owned subsidiaries: Vakston, Inc. and Diamune Therapeutics, Inc. Akston’s most advanced Animal Health candidates, AKS-321d and AKS-425c, are once-a-week insulins designed to treat canine and feline...
17Aug